|

Venetoclax (VEN) Clinical Trials

3 actively recruiting trials across 1 location

No change since May 2026

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1

Top Sponsors

  • Janssen Research & Development, LLC2
  • Technische Universität Dresden1

Indications

  • Cancer3
  • Leukemia, Myeloid, Acute2
  • Myelodysplastic Neoplasms1
  • AML - Acute Myeloid Leukemia1

Other2 trials

A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Phase 1
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Phase 2

Birmingham, Alabama1 trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

University of Alabama at Birmingham

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.